SCHEMBL7072249

SCHEMBL7072249

COc1ccc2c(=O)c(C)c(-c3ccccc3)oc2c1C(=O)C=Cc1ccc(C#N)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PADI4 Q9UM07 4/20 0.46
MAPT P10636 7/20 0.43
LMNA P02545 6/20 0.43
ALDH1A1 P00352 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HTT P42858 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
SRC P12931 1/20 0.42
PLIN1 O60240 1/20 0.42
GAA P10253 1/20 0.42
RAB9A P51151 1/20 0.42
PLIN5 Q00G26 1/20 0.42
ABHD5 Q8WTS1 1/20 0.42
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
BLM P54132 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7186435 0.79 PADI4 (0.41) PADI4MAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL7070595 0.78 MAOB (0.40) PADI4MAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL8876628 0.78 ALDH1A1 (0.52) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL7073031 0.78 ALDH1A1 (0.52) MAPTLMNAALDH1A1SMN1; SMN2GAA
SCHEMBL7072943 0.78 ALDH1A1 (0.41) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL7073297 0.78 MAOB (0.43) MAPTLMNAALDH1A1SMN1; SMN2GAA
SCHEMBL7192689 0.77 KRAS (0.42) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL7072948 0.76 KRAS (0.43) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL7075613 0.76 MAOB (0.42) MAPTLMNAALDH1A1SMN1; SMN2KMT2A
SCHEMBL7070128 0.76 KRAS (0.42) MAPTLMNAALDH1A1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6620842-B2 Chalcones INDENA SPA (IT) 2003-09-16 US disclosed
EP-1212315-B1 NOVEL CHALCONES INDENA SPA (IT) 2003-03-26 EP disclosed
US-20030055056-A1 For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth INDENA S.P.A. (IT) 2003-03-20 US disclosed
EP-1212315-A1 NOVEL CHALCONES INDENA S.p.A. (IT) 2002-06-12 EP disclosed
WO-2001017988-A1 NOVEL CHALCONES INDENA S.P.A. (IT) 2001-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055056-A1 For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth HDGF, MKI67, HPD PADI4 1510/4885MAPT 4477/4885LMNA 4635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.